Ridlip

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ridlip

Quick Facts

Property Description
Active ingredient Rosuvastatin (as Rosuvastatin Calcium)
Form Oral Tablet
Pharmacological class Statin (HMG-CoA Reductase Inhibitor)
Common use Management of Dyslipidemia
Origin Synthetic Compound

What is Ridlip and What is its Composition?

Ridlip is a pharmaceutical preparation containing the synthetic active ingredient Rosuvastatin (INN: Rosuvastatin Calcium), which is typically supplied as an oral tablet and requires a prescription. This compound is chemically defined as a dihydroxy monocarboxylic acid and a sulfonamide.

What Type of Medicine is Rosuvastatin?

Rosuvastatin is classified as a potent antilipemic agent belonging to the Statin class, formally known as HMG-CoA Reductase Inhibitors. This positioning is clinically recognized for efficacy in modifying blood lipid levels. Statins are typically utilized as first-line options for the treatment of dyslipidemia, a condition characterized by abnormal levels of fats, particularly high LDL cholesterol, in the bloodstream.

What is the General Purpose of This Class of Agents?

The primary general purpose of this medication class is to manage high levels of blood fats, specifically by reducing the liver’s internal production of circulating low-density lipoprotein (LDL) cholesterol. By mitigating this major factor in the formation of plaques in the arteries, these agents fulfill the overarching therapeutic goal of reducing the risk of major cardiovascular events such as heart attack and stroke. The verified actions of this class establish the drug's role in a comprehensive strategy to maintain circulatory health.

Regulatory References

  1. NIH Statins Overview

What side effects are possible with Ridlip?

Possible Side Effects and Safety Information

The safety profile of rosuvastatin (Ridlip) is organized by regulatory authorities based on the frequency and system-organ class of documented adverse reactions. The profile emphasizes both common expected effects and rare but serious risks, as outlined in official labeling from bodies like the FDA and EMA.


Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on their rate of occurrence in clinical data:

  • Common (affecting 1 to 10 users in 100): Includes symptoms such as headache, dizziness, nausea, constipation, abdominal pain, and myalgia (muscle aches).
  • Uncommon: Generally includes various hypersensitivity reactions (e.g., rash, itching).
  • Rare: Includes clinically significant events like myopathy (muscle disease), rhabdomyolysis (severe muscle breakdown), pancreatitis, and persistent elevation of liver enzymes.

Serious Safety Considerations

The regulatory profile highlights specific serious risks, particularly those related to the musculoskeletal and hepatobiliary systems. Rhabdomyolysis is a rare but severe muscle condition documented as a risk that may lead to acute renal issues. Cases of hepatitis and jaundice (liver injury) are also documented as rare events. The risk of muscle toxicity is officially documented as being dose-related, particularly with the highest available strength.

Safety Restrictions for Specific Populations

Rosuvastatin is contraindicated (should not be used) in patients with active liver disease or unexplained, persistent elevations of serum transaminases. The drug is also contraindicated during pregnancy and lactation. The label notes an increased systemic exposure in patients of Asian descent, which is considered in the administration strategy. Regulatory documents include requirements for liver function monitoring before and during the treatment course.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Ridlip indicates that data on human overdose are currently unavailable. Due to this lack of established human safety data at higher-than-recommended doses, management of a suspected overdose relies on general supportive measures.

Overdose Scope

Overdose Domain Official Regulatory Statement
Documented Presentations No specific human overdose presentations or symptom clusters are officially documented.
Physiological Systems Not explicitly detailed; management is based on general medical assessment.
Dose-Related Factors The amount of drug in a single dose associated with toxicity is not established in public regulatory text.
Emergency Response General supportive measures must be initiated as medically appropriate, including continuous monitoring of the patient's clinical status.

When Immediate Medical Help Is Required

Immediate medical attention must be sought in the event of suspected overdose. Patients should be taken to an emergency medical facility right away. The primary treatment approach is symptomatic and supportive care, in accordance with the standard clinical practice for acute drug exposure. No specific antidotes for Ridlip overdose are officially documented or recommended. This universal requirement to seek emergency medical care reflects the need for professional monitoring and supportive treatment for any drug where high-dose effects are not fully characterized.

Therapeutic Uses of Ridlip

Ridlip is commonly used to help manage elevated levels of cholesterol and triglycerides in the blood, often as part of a comprehensive management plan. Primary therapeutic use of this medication supports lipid management across conditions presenting with systemic or localized discomfort related to high cholesterol. This medication is considered relevant for easing the heightened physiological stress associated with cardiovascular risk.


Managing Elevated Blood Lipids

Ridlip is applied across domains where additional symptomatic support is needed in conditions presenting with systemic or localized discomfort related to high cholesterol. It is commonly used across conditions presenting with acute episodes related to lipid elevations. It assists with managing functional stability related to lipid levels, which is relevant for easing the systemic burden.


Management of Cardiovascular Risk

The medication is considered relevant for easing the heightened physiological stress associated with conditions marked by increased physiological stress affecting the circulatory system. Ridlip supports general well-being and is relevant for helping with the management of cardiovascular risk factors.


Quick Fact: Relief for Systemic Imbalance

Regulatory References

  1. NIH MedlinePlus Rosuvastatin Overview

Eligibility and Restrictions for Use

The official eligibility profile for Ridlip (rosuvastatin) is strictly defined by government regulatory bodies based on age, physiological status, and underlying medical conditions.

Contraindications (Must Not Use)

The medicine is formally contraindicated in the following populations as per regulatory labeling:

  • Pregnancy and Lactation: Women who are pregnant, may become pregnant, or are breastfeeding.
  • Active Liver Disease: Patients with active liver disease, including unexplained persistent elevations of liver enzymes.
  • Hypersensitivity: Individuals with a known allergy to rosuvastatin or any component of the formulation.

Eligibility and Restrictions

Age-Related Eligibility:

Population Eligibility Status (Official Labeling)
Adults Established Use.
Children (ge 8 years) Approved for Heterozygous Familial Hypercholesterolemia (HeFH).
Children (ge 7 years) Approved for Homozygous Familial Hypercholesterolemia (HoFH).
Children (<7-8 years) Use is not established for any indication.

Condition-Based Restrictions:

Patients with severe renal impairment (creatinine clearance <30 mL/min) are subject to dose restrictions, and the highest 40 mg strength is contraindicated in this group. Additionally, individuals of Asian descent may require a lower starting dose due to documented higher systemic exposure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Rosuvastatin (Ridlip) is subject to specific regulatory restrictions when co-administered with certain other products, primarily due to effects on drug concentration or additive safety risk.

Official Interaction Restrictions

Category Interacting Substance / Condition Regulatory Constraint
Contraindicated Combinations Specific Antiviral Combinations (e.g., Sofosbuvir/Velpatasvir/Voxilaprevir) Use is not recommended/contraindicated due to significant increase in Rosuvastatin exposure.
Additive Risk Gemfibrozil (Fibrate) Co-administration should be avoided; if used, the Rosuvastatin dose must be strictly limited.
Exposure Elevation Cyclosporine (Immunosuppressant) Leads to a significant increase in Rosuvastatin plasma levels; maximum allowed Rosuvastatin dose is strictly limited to 5 mg once daily.

Pharmacokinetic and Population Constraints

The most clinically significant interactions are transporter-mediated, involving the inhibition of hepatic uptake transporters OATP1B1 and BCRP by certain co-administered medicines, which results in the documented increase of Rosuvastatin exposure. The drug's clearance is not dependent on the CYP3A4 enzyme to a clinically significant extent.

Specific timing separation rules apply to Antacids containing aluminum or magnesium hydroxide, which must be administered at least two hours after Rosuvastatin to prevent a documented reduction in absorption. Additionally, the label notes that the risk of interaction is heightened in Asian patients due to documented higher systemic exposure, and the 40 mg dose is contraindicated in patients with severe renal impairment.

Mechanism of Action

Hepatic Enzyme Inhibition and Lipid Clearance

Ridlip's active ingredient, Rosuvastatin, acts as a competitive and reversible inhibitor of HMG-CoA Reductase, the rate-limiting enzyme in the liver's cholesterol synthesis pathway. By blocking this molecular step, the drug depletes the internal cholesterol concentration within hepatocytes. In response, the liver upregulates the expression of LDL Receptors on its surface, which enhances the clearance and catabolism of circulating Low-Density Lipoprotein Cholesterol (LDL-C) from the bloodstream. This core mechanism results in a reduction of LDL-C and Very Low-Density Lipoprotein Cholesterol (VLDL-C) concentrations.

Vascular and Anti-inflammatory Pathway Modulation

Beyond its primary lipid-lowering cascade, the mechanism of Rosuvastatin engages in non-cholesterol-dependent effects, often referred to as pleiotropic actions. The inhibition of HMG-CoA Reductase reduces the production of downstream signaling molecules called isoprenoids. This limits the activation of small GTP-binding proteins (like Rho/Rac), leading to the stabilization of Endothelial Nitric Oxide Synthase (eNOS). The mechanism results in the modulation of endothelial function, a reduction in oxidative stress, and the attenuation of systemic inflammatory markers, influencing the drug's overall physiological profile.

Dosage and Administration Information

How to Use Ridlip: Official Administration Guidelines

Rosuvastatin (Ridlip) is an oral tablet used according to specific administration guidelines.

Administration and Frequency

Rosuvastatin is taken once daily and can be administered at any time of the day, either with or without food. The tablet must be swallowed whole and should not be crushed or chewed, as this practice is not compliant with standard administration instructions. If a dose is missed, individuals should not take an extra dose to compensate; therapy is simply resumed with the next scheduled daily dose.

Standard Dosing and Adjustment

Therapy typically begins with a dose of 10 mg or 20 mg once daily for adults, although a lower starting dose of 5 mg may be considered in some regions and patient populations. The dosage is typically adjusted every 2 to 4 weeks based on the evaluation of lipid response. The maximum recommended daily dose for Rosuvastatin is 40 mg, which is reserved for patients who have not achieved their treatment goals with the 20 mg dose.

Population-Specific Dosing

Specific adjustments to the dosing schedule are required for certain groups:

  • Severe Renal Impairment: For patients with severe kidney dysfunction (non-dialysis), the recommended starting dose is 5 mg, and the dose should not exceed 10 mg once daily.
  • Asian Patients: A 5 mg starting dose is often considered due to the potential for increased systemic exposure.

These guidelines establish the structured, long-term protocol for the administration of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ridlip


Evidence for Use in Studies Examining High Cholesterol and Triglycerides

The research into the use of Ridlip was evaluated in studies exploring high cholesterol and triglycerides, primarily based on Randomized Controlled Trials (RCTs). These short-term and intermediate-term studies explored how lipid biomarkers—specifically levels of LDL-C (Low-Density Lipoprotein Cholesterol) and triglycerides—were measured in adult patients with high lipid levels. Findings describe patterns observed in the studies related to the measurement of pre-specified cholesterol goals set by guideline bodies. Comparative evidence between all individual statins regarding long-term cardiovascular outcomes is limited, and results apply primarily to the specific populations studied within the trials.


Evidence for Use in Studies Examining Major Cardiovascular Events

The most comprehensive research for Ridlip is based on large, long-term Randomized Controlled Trials and subsequent systematic reviews. These studies monitored outcomes related to physical discomfort and systemic or functional imbalance in at-risk populations. Long-term trials examined the reported frequency of Major Adverse Cardiovascular Events (MACE), including monitoring outcomes such as heart attack and stroke. Research describes patterns related to the reported frequency of these events over follow-up durations typically several years.

While event rates are well-documented for the core study populations over intermediate time frames, there is limited information for long-term outcomes extending beyond the typical four- to five-year study duration. The findings reflect the specific conditions and strict inclusion criteria under which these studies were conducted, meaning results apply only to the populations studied.


Key Limitations and Areas of Uncertainty

Comparative evidence is limited for head-to-head comparisons of the long-term effectiveness of Ridlip versus every other statin at every possible dose regarding major cardiovascular outcomes. Special populations, such as pediatric patients with inherited high cholesterol, have been examined in smaller trials. Data for these groups remain insufficient to fully establish the impact on cardiovascular events later in life, meaning certainty is still being established in these areas.

Frequently Asked Questions (FAQ)

Common questions about Ridlip (FAQ)


Q: How quickly does Ridlip start working after taking it?

Studies and official information indicate that the initial effects on cholesterol levels may begin within a few days of starting treatment. However, the full intended therapeutic effect is typically measured and monitored after approximately four weeks of consistent, regular use.

Q: What should I do if I get muscle aches while taking Ridlip?

Official labeling notes that muscle aches (myalgia) are a common side effect of this medicine. Official labeling indicates that patients should promptly report any unexplained muscle pain, tenderness, or weakness to a healthcare provider, especially if these symptoms are accompanied by a fever or general feeling of illness (malaise).

Q: Can Ridlip interact with grapefruit or grapefruit juice?

Regulatory-sourced patient information indicates that consumption of grapefruit or grapefruit juice is generally considered acceptable while taking this medicine.

Q: What should I tell my doctor before starting Ridlip?

Official regulatory text highlights several conditions that should be discussed with a healthcare provider before starting treatment. These include any history of liver or kidney problems, severe muscle conditions, or thyroid issues. Official information states that a healthcare provider should be informed regarding pregnancy status, plans for pregnancy, or breastfeeding, and all other prescription or non-prescription medicines being taken.

Q: What are the signs of an allergic reaction to Ridlip?

Signs of an allergic reaction documented in official information may include skin symptoms like rash, hives, or itching. More serious reactions involve sudden swelling of the face, lips, tongue, or throat, or difficulty breathing or swallowing. If a serious allergic reaction is suspected, official sources emphasize that prompt medical evaluation is important.

Q: Can Ridlip cause a rash or skin problems?

The safety profile documents rash and skin problems, including hives, as uncommon hypersensitivity reactions. While not everyone experiences them, these types of reactions are documented in the official regulatory data.

Q: Is Ridlip known to interact with herbal supplements?

Official patient information generally recommends discussing all non-prescription products, including herbal supplements, multivitamins, or fish oil, with a healthcare provider. Official guidance indicates that certain supplements, such as St. John's wort or Red Yeast Rice, may affect the medicine’s concentration in the body or increase the documented risk of side effects.

Q: What is the difference between Ridlip and [Competitor Drug Name]?

Regulatory sources do not provide direct comparative recommendations between this medicine and others. This medicine belongs to the statin class, which works in a similar way to modify lipid levels. Official research describes limited head-to-head comparisons for long-term cardiovascular outcomes between all individual statins.

Q: Is it true that Ridlip is only for people with high cholesterol?

According to official documents, the medicine has two primary uses. In addition to treating high cholesterol and other abnormal lipid levels, it is also indicated to reduce the risk of major cardiovascular events in certain populations considered to be at high risk.

Q: Does Ridlip affect energy levels or cause tiredness?

The official adverse reaction profile lists asthenia as a frequent side effect reported in clinical trial data. Asthenia is a medical term that refers to an abnormal feeling of physical weakness or a general lack of energy.

Q: Are there any long-term studies on using Ridlip?

Yes, large, long-term studies have examined the use of this medicine over several years. These clinical trials monitored the medicine’s effect on the risk of major cardiovascular events in specific populations, providing long-term data on its use.

Q: Do I need to change my diet while taking Ridlip?

The official use of this medicine is generally recommended in conjunction with appropriate dietary changes. Regulatory patient information advises that it should be part of a comprehensive lifestyle program to help manage cholesterol levels.

Q: Does taking Ridlip affect blood sugar levels?

Research has examined the relationship between this class of medicine and blood sugar. Official patient information notes that its use may be associated with a small increase in blood glucose in some individuals.

Q: Does Ridlip work by lowering LDL or raising HDL?

The medicine is documented to primarily reduce the concentrations of 'bad' cholesterol (LDL-C) and VLDL-C. Additionally, official sources indicate that its action may also be associated with a modest increase in 'good' cholesterol (HDL-C) levels.

Q: Why do official documents mention 'unknown risk' for Ridlip in certain situations?

Regulatory documentation often refers to areas where research data is limited or ongoing. This includes the long-term impact on cardiovascular events or the effect on endocrinology function in specific patient groups, such as pediatric patients.

Q: Does Ridlip interact with blood thinners like warfarin?

Yes, official labeling states that this medicine interacts with warfarin, which is a blood-thinning medication. Specific monitoring of the International Normalized Ratio (INR) is generally required upon starting, adjusting, or stopping the medicine.

Q: How long do most people stay on Ridlip treatment?

Treatment with this medicine is typically considered a long-term commitment. Official documentation indicates that the medicine is typically intended to be taken consistently over an extended period to support the intended cholesterol-lowering and cardiovascular outcomes.

Q: What does the FDA's Black Box Warning mean for Ridlip, if it has one?

Official FDA labeling for this medicine does not currently include a Boxed Warning, which is sometimes referred to as a Black Box Warning. This formal designation is reserved for certain medications that carry specific, serious risks.

Q: Is there a specific mechanism that makes Ridlip different from statins?

The core action of the medicine is the same as the statin class, involving the inhibition of the HMG-CoA Reductase enzyme. However, official pharmacological data describes it as being hydrophilic and less reliant on the CYP3A4 enzyme for metabolism than some other statins.

Q: What is the general success rate reported in clinical trials for Ridlip?

Research from large clinical studies documents a statistically significant reduction in cardiovascular outcomes in the studied populations. This evidence was sufficient to result in some trials being discontinued early, as reported in regulatory evidence summaries.

How should Ridlip be stored and disposed of?

How to Store and Dispose of Ridlip

Official regulatory documents define strict requirements for storing, handling, and disposing of this medicine.

Storage Requirements

Requirement Regulatory Statement
Temperature Control Must not be stored at temperatures above 30°C.
Child Safety Must be stored out of sight and reach of children.
Expiration Do not use this medicine after the expiry date stated on the packaging.

Disposal Instructions

Proper disposal is required to prevent environmental contamination:

  • Do not dispose of this medicine via wastewater (such as flushing down a toilet) or place it in regular household waste.
  • The unused or expired product should be discarded through an appropriate pharmaceutical take-back scheme or collection program as mandated by local regulations.

These mandated conditions ensure the medicine remains stable and effective until its expiration date and safeguard against improper use or environmental harm.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ridlip found in:

A-Z Index: